Clinical Trial Update: Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study [Phase 2]

View source ↗

Summary

Phase II open-label study evaluating the efficacy and safety of a combination of anlotinib, irinotecan, and temozolomide in children with refractory or recurren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Anlotinib (anlotinib)
• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Refractory or Recurrent Neuroblastoma in Children | Phase 2 | Status: UNKNOWN